Eli Lilly (LLY.US) stated that after its experimental glucagon-like peptide-1 weight loss drug showed positive results in mid-stage studies, it will begin late-stage trials next month.
The company indicated that weekly injections of the maximum dose of eloralin can help obese or overweight patients lose an average of 20.1% of their weight over 48 weeks

Eli Lilly stated that after its experimental insulin weight-loss drug showed positive results in mid-term studies, it will begin late-stage trials next month. The company indicated that the highest weekly dose of Irlaglutide can help obese or overweight patients lose an average of 20.1% of their weight over 48 weeks

Eli Lilly will launch late-stage trials for its amylin-based weight loss drug